Molecular Financial Statements From 2010 to 2024
| MOLN Stock | CHF 3.36 0.16 5.00% |
Check Molecular Partners financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Molecular main balance sheet or income statement drivers, such as , as well as many exotic indicators such as . Molecular financial statements analysis is a perfect complement when working with Molecular Partners Valuation or Volatility modules.
Molecular |
Molecular Partners AG Company Return On Asset Analysis
Molecular Partners' Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current Molecular Partners Return On Asset | 0.32 |
Most of Molecular Partners' fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Molecular Partners AG is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
| Competition |
Based on the latest financial disclosure, Molecular Partners AG has a Return On Asset of 0.3163. This is 103.61% lower than that of the Healthcare sector and 101.34% lower than that of the Biotechnology industry. The return on asset for all Switzerland stocks is notably lower than that of the firm.
Molecular Partners Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Molecular Partners's current stock value. Our valuation model uses many indicators to compare Molecular Partners value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Molecular Partners competition to find correlations between indicators driving Molecular Partners's intrinsic value. More Info.Molecular Partners AG is considered to be number one stock in return on equity category among related companies. It is considered to be number one stock in return on asset category among related companies reporting about 0.51 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Molecular Partners AG is roughly 1.97 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Molecular Partners by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Molecular Partners' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Molecular Partners' earnings, one of the primary drivers of an investment's value.About Molecular Partners Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Molecular Partners income statement, its balance sheet, and the statement of cash flows. Molecular Partners investors use historical funamental indicators, such as Molecular Partners's revenue or net income, to determine how well the company is positioned to perform in the future. Although Molecular Partners investors may use each financial statement separately, they are all related. The changes in Molecular Partners's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Molecular Partners's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Molecular Partners Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Molecular Partners. Please read more on our technical analysis and fundamental analysis pages.
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland. MOLECULAR PARTNERS operates under Biotechnology classification in Switzerland and is traded on Switzerland Exchange. It employs 163 people.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out the analysis of Molecular Partners Correlation against competitors. You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Complementary Tools for Molecular Stock analysis
When running Molecular Partners' price analysis, check to measure Molecular Partners' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Molecular Partners is operating at the current time. Most of Molecular Partners' value examination focuses on studying past and present price action to predict the probability of Molecular Partners' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Molecular Partners' price. Additionally, you may evaluate how the addition of Molecular Partners to your portfolios can decrease your overall portfolio volatility.
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Stocks Directory Find actively traded stocks across global markets | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets |